Phenobarbital for the management of severe acute alcohol withdrawal (the PHENOMANAL trial): a pilot randomized controlled trial

BACKGROUND: Benzodiazepines are considered first-line treatment for patients experiencing severe acute alcohol withdrawal syndrome (sAAWS). Although several medications have been evaluated as potential adjuvant treatments for sAAWS, barbiturates show particular promise. OBJECTIVE: In the PHENOMANAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Filewod, Niall, Hwang, Stephen, Turner, Christian J., Rizvi, Leena, Gray, Sara, Klaiman, Michelle, Buell, Danielle, Ailon, Johnathan, Caudarella, Alexander, Ginocchio, Galo F., Santos, Marlene, Sandhu, Gyan, Dewhurst, Norman, Sequeira, Kelly, Burns, Karen E. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783453/
https://www.ncbi.nlm.nih.gov/pubmed/35065662
http://dx.doi.org/10.1186/s40814-021-00963-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783453/
https://www.ncbi.nlm.nih.gov/pubmed/35065662
http://dx.doi.org/10.1186/s40814-021-00963-4

Ejemplares similares